View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 01, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		61,726,370

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 85,465	$ 88,438
Short-term investments	78,215	68,134
Accounts receivable, net of allowance for doubtful accounts of $2,501 and $418	27,764	34,842
Inventories	25,040	22,888
Prepaid expenses	1,830	1,925
Other current assets	4,966	3,085
Total current assets	223,280	219,312
Noncurrent Assets:
Property, plant and equipment, net	29,045	24,299
Operating right-of-use assets, net	3,574
Finance right-of-use assets, net	1,276
Intangible assets, net	11,577	5,137
Goodwill	28,935	18,521
Long-term investments	37,563	44,752
Other noncurrent assets	3,971	3,550
Total noncurrent assets	115,941	96,259
TOTAL ASSETS	339,221	315,571
Current Liabilities:
Accounts payable	9,783	10,598
Deferred revenue	3,940	3,521
Accrued expenses and other current liabilities	10,974	13,861
Finance lease liability	439
Operating lease liability	761
Acquisition-related contingent consideration obligation	3,039
Total current liabilities	28,936	27,980
Noncurrent Liabilities:
Finance lease liability	829
Operating lease liability	3,053
Acquisition-related contingent consideration obligation	385
Other noncurrent liabilities	3,575	3,312
Deferred income taxes	1,078	901
Total noncurrent liabilities	8,920	4,213
TOTAL LIABILITIES	37,856	32,193
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 61,726 and 61,276 shares issued and outstanding	0	0
Additional paid-in capital	401,014	401,273
Accumulated other comprehensive loss	(14,678)	(18,706)
Accumulated deficit	(84,971)	(99,189)
Total stockholders' equity	301,365	283,378
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 339,221	$ 315,571

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 2,501	$ 418
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	61,726,000	61,276,000
Common stock, shares outstanding	61,726,000	61,276,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
NET REVENUES:
Total revenue	$ 35,989	$ 45,885	$ 104,937	$ 131,497
COST OF PRODUCTS SOLD	14,343	17,340	40,193	52,590
Gross profit	21,646	28,545	64,744	78,907
OPERATING EXPENSES:
Research and development	4,619	3,855	13,525	12,191
Sales and marketing	8,955	7,304	23,937	22,232
General and administrative	7,556	6,529	23,748	28,567
Change in the estimated fair value of acquisition-related contingent consideration	(2,387)		(843)
Gain on sale of business	(10,149)		(10,149)
Total operating expenses	8,594	17,688	50,218	62,990
Operating income	13,052	10,857	14,526	15,917
OTHER INCOME	1,195	510	2,243	1,658
Income before income taxes	14,247	11,367	16,769	17,575
INCOME TAX EXPENSE	1,169	3,271	2,551	7,477
NET INCOME	$ 13,078	$ 8,096	$ 14,218	$ 10,098
EARNINGS PER SHARE:
BASIC	$ 0.21	$ 0.13	$ 0.23	$ 0.17
DILUTED	$ 0.21	$ 0.13	$ 0.23	$ 0.16
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	61,726	61,208	61,656	61,059
DILUTED	62,143	62,606	62,172	62,539
Products and Services [Member]
NET REVENUES:
Total revenue	$ 35,299	$ 43,450	$ 100,898	$ 120,586
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 690	$ 2,435	$ 4,039	$ 10,911

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME	$ 13,078	$ 8,096	$ 14,218	$ 10,098
OTHER COMPREHENSIVE INCOME
Currency translation adjustments	(1,557)	1,783	3,151	(2,023)
Unrealized gain (loss) on marketable securities	194	(34)	877	(352)
COMPREHENSIVE INCOME	$ 11,715	$ 9,845	$ 18,246	$ 7,723

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
OPERATING ACTIVITIES:
Net income		$ 14,218	$ 10,098
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation		3,283	12,526
Depreciation and amortization		5,532	5,588
Provision for doubtful accounts		2,083	(179)
Unrealized foreign currency (gain)/loss		272	(48)
Interest expense on finance leases	$ 10	23
Deferred income taxes		(291)	(415)
Loss on sale of fixed assets		145
Gain on sale of business	(10,149)	(10,149)
Change in the estimated fair value of acquisition-related contingent consideration	(2,387)	(843)
Changes in assets and liabilities
Accounts receivable		5,730	9,011
Inventories		(3,255)	(649)
Prepaid expenses and other assets		1,438	615
Accounts payable		(1,042)	(2,179)
Deferred revenue		348	1,741
Accrued expenses and other liabilities		(6,654)	(11,302)
Net cash provided by operating activities		10,838	24,807
INVESTING ACTIVITIES:
Purchases of investments		(92,173)	(135,625)
Proceeds from maturities and redemptions of investments		91,451	124,071
Purchases of property and equipment	(2,448)	(7,961)	(5,938)
Acquisition of businesses, net of cash acquired		(13,217)
Proceeds from sale of business		12,000
Net cash used in investing activities		(9,900)	(17,492)
FINANCING ACTIVITIES:
Repayments of loans		(724)
Cash payments for lease liability	(129)	(253)
Proceeds from exercise of stock options		169	1,684
Repurchase of common stock		(3,711)	(3,181)
Net cash used in financing activities		(4,519)	(1,497)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		608	(541)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(2,973)	5,277
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		88,438	72,869
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 85,465	85,465	78,146
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes		7,470	14,482
Non-cash investing and financing activities
Accrued property and equipment purchases		477	592
Unrealized gain (loss) on marketable securities		$ 877	$ (352)

The Company

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	The Company

Our business is composed of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays, and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets, and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets.

Our OSUR diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. We also previously manufactured and sold medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products were sold in both professional and over-the-counter (“OTC”) markets in North America, Europe, Central and South America, and Australia. We sold the assets associated with our cryosurgical systems business to a third party in August 2019. See further discussion at Note 4.

Our DNAG or molecular collection systems business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), CoreBiome Inc. (“CoreBiome”), and Novosanis NV (“Novosanis”). DNAG’s specimen collection devices provide all-in-one systems for the collection, stabilization, transportation and storage of nucleic acids from human saliva and other sample types for genetic and microbiome applications. Novosanis’ Colli-Pee collection device is designed for the volumetric collection of first-void urine for use in research, screening and diagnostics for the liquid biopsy and sexually transmitted disease markets. We also sell research use only sample collection products into the microbiome market and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide in the research, healthcare, pharmaceutical and agricultural communities.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, CoreBiome, and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale debt securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of September 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2019
Guaranteed investment certificates	$	24,181	$	—	$	—		$	24,181
Corporate bonds		91,637		286		(326	)		91,597
Total available-for-sale securities	$	115,818	$	286	$	(326	)	$	115,778
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At September 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	78,271	$	183	$	(239	)	$	78,215
Greater than one year	$	37,547	$	103	$	(87	)	$	37,563

Fair Value of Financial Instruments. As of September 30, 2019 and December 31, 2018, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2019 and December 31, 2018.

Included in cash and cash equivalents at September 30, 2019 and December 31, 2018, was $18,790 and $21,631 invested in government money market funds and certificates of deposit. Both are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2019 and December 31, 2018 was $4,280 and $3,884, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

See Note 3 for discussion of the contingent consideration liabilities.

Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	September 30, 2019		December 31, 2018
Raw materials	$	14,425	$	14,092
Work in process		838		544
Finished goods		9,777		8,252
	$	25,040	$	22,888

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of September 30, 2019 and December 31, 2018 was $45,533 and $42,797, respectively.

Intangible Assets. Intangible assets consist of customer lists, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of September 30, 2019 and December 31, 2018 was $22,410 and $20,105, respectively. The change in intangibles from $5,137 as of December 31, 2018 to $11,577 as of September 30, 2019 is a result of intangibles acquired in our acquisitions of CoreBiome and Novosanis of $8,400 offset by foreign currency translation losses of $129 and $1,831 in amortization expense.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisitions of DNAG, CoreBiome, and Novosanis. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The increase in goodwill from $18,521 as of December 31, 2018 to $28,935 as of September 30, 2019 is a result of the additional goodwill associated with our acquisitions of CoreBiome and Novosanis of $9,994 and an increase of $420 associated with foreign currency translation. All acquired goodwill has been allocated to our DNAG segment.

Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and will not restate comparative amounts. Also, we elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. Leases with an initial term of 12 months or less are not recognized on the balance sheet and the associated lease payments are included in the consolidated statements of operations on a straight-line basis over the lease term. As a result, on January 1, 2019, we recorded right-of-use assets of $4,027 and lease liabilities of $4,263 on our consolidated balance sheet.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2019		2018		2019		2018

Net income	$	13,078	$	8,096	$	14,218	$	10,098
Weighted-average shares of common stock outstanding:
Basic		61,726		61,208		61,656		61,059
Dilutive effect of stock options, restricted stock, and performance stock units		417		1,398		516		1,480
Diluted		62,143		62,606		62,172		62,539
Earnings per share:
Basic	$	0.21	$	0.13	$	0.23	$	0.17
Diluted	$	0.21	$	0.13	$	0.23	$	0.16

For the three months ended September 30, 2019 and 2018, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 909 and 304 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2019 and 2018, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 709 and 256 shares, respectively, were similarly excluded from the computation of diluted earnings per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $50 and $(375) for the three months ended September 30, 2019 and 2018, respectively. Net foreign exchange gains (losses) were $(875) and $(30) for the nine months ended September 30, 2019 and 2018, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at September 30, 2019 consists of $14,638 of currency translation adjustments and $40 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2018 consists of $17,789 of currency translation adjustments and $917 of net unrealized losses on marketable securities.

Recent Accounting Pronouncements

In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The guidance is effective beginning in fiscal year 2020, with early adoption permitted beginning in fiscal year 2019. We are evaluating the impact this guidance will have on our consolidated financial statements.

In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. The guidance is effective in fiscal year 2020, with early adoption permitted, including adoption in an interim period. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We are evaluating the impact of this guidance and expect no impact to our consolidated financial statements.

Business Combinations

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.

During the nine months ended September 30, 2019, we incurred a total of $597 of acquisition-related costs, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income.

Pursuant to our acquisition agreements, we may pay up to an additional $32,400 of contingent consideration over the next three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculates the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return

analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The change in the fair value of the contingent consideration obligation from $4,350 as of the acquisition date to $3,424 as of September 30, 2019 is a result of changes in our estimated revenue forecasts, offset by the probability associated with achieving a certain technical milestone. In October 2019, management agreed to settle the contingent consideration associated with one of the acquisition’s 2019 results for $3,500, which will result in an increase of approximately $500 in the fair market value of the related contingent consideration liability in the fourth quarter of 2019.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.

The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

The amortization of intangible assets is not deductible for income tax purposes.

Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.

We continue to evaluate the fair value of certain assets acquired and liabilities assumed, including the fair valuation of deferred tax assets acquired, related to the acquisition. Additional information, which existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.

Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. For the three and nine months ended September 30, 2019, consolidated net revenues include combined revenues associated with the CoreBiome and Novosanis business were $1,437 and $3,482, respectively. Consolidated results from operations for the three and nine months ended September 30, 2019 included net income (loss) of $1,377 and $(1,142), respectively, generated from the combined companies since the acquisition date. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.

Unaudited Pro Forma Financial Information

The unaudited pro forma results presented below include the results of the CoreBiome and Novosanis acquisitions as if they had been consummated as of January 1, 2018. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2018.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018

Revenue	$	35,989	$	46,628	$	104,937	$	133,150
Net income		13,078		7,649		14,218		7,335
Net income per share, basic and diluted		0.21		0.12		0.23		0.11

Sale of Cryosurgical Systems Business

9 Months Ended

Sep. 30, 2019

Discontinued Operations And Disposal Groups [Abstract]

Sale of Cryosurgical Systems Business

4. Sale of Cryosurgical Systems Business

On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical systems line of business to CryoConcepts LP (“CryoConcepts”) for $12,000. This business consisted of medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The products were sold in both the professional and OTC markets in North America, Europe, Central and South America and Australia. We also entered into a transition services agreement with CryoConcepts in which both parties agreed to provide certain transition services beginning after the closing. The Company recorded a gain on sale of business of $10,149 reflected in our statement of income for the quarter and year ended September 30, 2019. The gain includes the $12,000 of proceeds net of the fair value of the assets sold, which consisted entirely of inventory and fully-depreciated fixed assets, the legal fees associated with the transaction, and a value attributed to the transition services.

Revenues

9 Months Ended

Sep. 30, 2019

Revenue From Contract With Customer [Abstract]

Revenues

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019		2018
OraQuick®	$	13,256		$	12,016	$	37,813	$	40,813
Oragene®		11,590			22,450		27,316		52,799
ORAcollect®		2,489			1,353		9,032		3,460
Intercept®		2,230			1,743		6,144		5,811
Histofreezer® (through August 16, 2019)		569			2,199		5,718		6,526
Other products		5,165			3,689		14,875		11,177
Net product revenues		35,299			43,450		100,898		120,586

Royalty income		758			1,132		2,956		4,827
Research and development funding		(183	)		1,083		679		4,540
Charitable support reimbursement		85			220		203		1,544
Grant funding		30			-		201		-
Other revenues		690			2,435		4,039		10,911
Net revenues	$	35,989		$	45,885	$	104,937	$	131,497

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	26,245	$	36,883	$	74,712	$	99,860
Europe		2,767		1,982		8,188		7,187
Other regions		6,977		7,020		22,037		24,450
	$	35,989	$	45,885	$	104,937	$	131,497

Customer and Vendor Concentrations. One of our customers accounted for 24% of our accounts receivable as of September 30, 2019. The same customer accounted for approximately 17% and 11% of our net consolidated revenues for the three and nine months ended September 30, 2019 and 39% and 27% of our net consolidated revenues for the three and nine months ended September 30, 2018.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its product. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2019 and December 31, 2018 includes customer prepayments of $2,150 and $2,057, respectively. Deferred revenue as of September 30, 2019 and December 31, 2018 also includes $ 1,790 and $1,464, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

6.	Accrued Expenses and other current liabilities

	September 30, 2019		December 31, 2018
Payroll and related benefits	$	6,250	$	8,926
Professional fees		1,101		1,541
Income taxes payable		74		1,447
Other		3,549		1,947
	$	10,974	$	13,861

Credit Facility

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Credit Facility

7.	Credit Facility

On March 29, 2019, we terminated our credit agreement with a commercial bank which was entered into on September 30, 2016 and had a maturity date of September 30, 2019.

Leases

9 Months Ended

Sep. 30, 2019

Lessee Disclosure [Abstract]

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and will not restate comparative amounts.

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of September 30, 2019, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 8 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
Operating Lease Cost	$	232	$	695
Finance Lease Cost
Amortization of right-of use assets		112		264
Interest on lease liabilities		10		23
Total Finance Lease Cost	$	122	$	287

Lease cost for the three and nine months ended September 30, 2018 was $368 and $1,097.

Supplemental cash flow information related to leases is as follows:

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	232	$	690
Operating cash flows from financing leases		10		23
Financing cash flows from financing leases		129		253
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		-		240
Right-of-use assets obtained in exchange for finance lease obligations		-		1,249

Supplemental balance sheet information related to leases is as follows:

	September 30, 2019
Operating Leases
Right-of-use assets	$	3,574

Current lease liabilities		761
Non-current lease liabilities		3,053
Total operating lease liabilities	$	3,814


Finance Leases
Right-of-use assets	$	1,276

Current lease liabilities		439
Non-current lease liabilities		829
Total finance lease liabilities	$	1,268

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.89
Weighted-average remaining lease term—finance leases	3.25

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.23	%
Weighted-average discount rate—finance leases	2.82	%

As of September 30, 2019, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2019 (excluding the nine months ended September 30, 2019)	$	120		$	231
2020		454			951
2021		325			923
2022		324			898
2023		94			542
Thereafter		4			807
Total Minimum Lease Payments		1,321			4,352
Less: imputed interest		(53	)		(538	)
Present Value of Lease Liabilities	$	1,268		$	3,814

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Stockholders' Equity

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Stockholders' Equity

9.	Stockholders’ Equity

Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2019 and 2018
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Compensation cost for restricted stock		—			—		653			—			—			653
Compensation cost for stock option grants		—			—		324			—			—			324
Compensation cost for performance stock units		—			—		254			—			—			254
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Compensation cost for restricted stock		—			—		874			—			—			874
Compensation cost for stock option grants		—			—		311			—			—			311
Compensation cost for performance stock units		—			—		(569	)		—			—			(569	)
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments										2,476						2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221
Common stock issued upon exercise of options		-			—		—			—			—			-
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(7	)		—			—			(7	)
Compensation cost for restricted stock		-			—		858			—			—			858
Compensation cost for stock option grants		-			—		259			—			—			259
Compensation cost for performance stock units		-			—		319			—			—			319
Net income		-			—		—			—			13,078			13,078
Currency translation adjustments										(1,557	)					(1,557	)
Unrealized gain on marketable securities		-			—		—			194			—			194
Balance at September 30, 2019		61,726		$	—	$	401,014		$	(14,678	)	$	(84,971	)	$	301,365


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2017		60,662		$	—	$	387,931		$	(10,340	)	$	(119,510	)	$	258,081
Adoption of ASU 2014-9													(75	)		(75	)
Common stock issued upon exercise of options		133			—		974			—			—			974
Vesting of restricted stock and performance stock units		407			—		—			—			—			—
Purchase and retirement of common shares		(149	)		—		(2,959	)		—			—			(2,959	)
Compensation cost for restricted stock		—			—		3,626			—			—			3,626
Compensation cost for stock option grants		—			—		900			—			—			900
Compensation cost for performance stock units		—			—		2,957			—			—			2,957
Net loss		—			—		—			—			(2,119	)		(2,119	)
Currency translation adjustments										(2,154	)					(2,154	)
Unrealized loss on marketable securities		—			—		—			(512	)		—			(512	)
Balance at March 31, 2018		61,053		$	—	$	393,429		$	(13,006	)	$	(121,704	)	$	258,719
Common stock issued upon exercise of options		29			—		222			—			—			222
Vesting of restricted stock and performance stock units		106			—		—			—			—			—
Purchase and retirement of common shares		(14	)		—		(212	)		—			—			(212	)
Compensation cost for restricted stock		—			—		1,419			—			—			1,419
Compensation cost for stock option grants		—			—		475			—			—			475
Compensation cost for performance stock units		—			—		1,885			—			—			1,885
Net income		—			—		—			—			4,121			4,121
Currency translation adjustments										(1,652	)					(1,652	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at June 30, 2018		61,174		$	—	$	397,218		$	(14,464	)	$	(117,583	)	$	265,171
Common stock issued upon exercise of options		62			—		483			—			—			483
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(9	)		—			—			(9	)
Compensation cost for restricted stock		—			—		589			—			—			589
Compensation cost for stock option grants		—			—		359			—			—			359
Compensation cost for performance stock units		—			—		316			—			—			316
Net income		—			—		—			—			8,096			8,096
Currency translation adjustments										1,783						1,783
Unrealized loss on marketable securities		—			—		—			(34	)		—			(34	)
Balance at September 30, 2018		61,237		$	—	$	398,956		$	(12,715	)	$	(109,487	)	$	276,754

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation

expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation cost related to stock options for the nine months ended September 30, 2019 and 2018 was $894 and $1,734 respectively.

Compensation cost of $2,385 and $5,634 related to restricted shares was recognized during the nine months ended September 30, 2019 and 2018, respectively. In connection with the vesting of restricted shares during the nine months ended September 30, 2019 and 2018, we purchased and immediately retired 289 and 164 shares with aggregate values of $3,711 and $3,181, respectively, in satisfaction of minimum tax withholding obligations.

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period is based on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation cost of $4 and $5,158 related to PSUs was recognized during the nine months ended September 30, 2019 and 2018, respectively.

Modification of Grants

Stock compensation costs for the nine months ended September 30, 2018 include the additional expense associated with modifications of existing grants held by our retired President and Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”). These additional costs were $8,039 during the nine months ended September 30, 2018, and are included in general and administrative expenses in the accompanying consolidated statement of income.

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the nine months ended September 30, 2019 and 2018.

Income Taxes

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

10.	Income Taxes

During the three and nine months ended September 30, 2019, we recorded income tax expense of $1,169 and $2,551, respectively. During the three and nine months ended September 30, 2018, we recorded tax expense of $3,271 and $7,477, respectively.

Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2019 and December 31, 2018 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both September 30, 2019 and December 31, 2018 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three and nine month period ended September 30, 2019.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11.	Commitments and Contingencies

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Transition Costs

9 Months Ended

Sep. 30, 2019

Transition Costs [Abstract]

Transition Costs

12.	Transition Costs

In January 2018, we announced the retirement of Douglas A. Michels, our then President and CEO, and Ronald H. Spair, our then CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Mr. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Mr. Spair, who retired as CFO and Chief Operating Officer, and as a member of our Board of Directors, on that same date. Charges associated with

these transitions were $8,628 during the nine months ended September 30, 2018 and are included in general and administrative expenses in the accompanying consolidated statement of income. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO. No related transition costs were recorded during the nine months ended September 30, 2019.

Business Segment Information

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Business Segment Information

13.	Business Segment Information

Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment. Our cryosurgical system business was included in our OSUR segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

Operating income (loss) for the three and nine months ended September 30, 2018 has been modified to conform to the classification of the intercompany service fee presentation for 2019. Beginning with the first quarter of 2019, we have included the fees for intercompany services in our segment operating income (loss) in order to more accurately reflect the results of each segment.

The following table summarizes operating segment information for the three and nine months ended September 30, 2019 and 2018, and asset information as of September 30, 2019 and December 31, 2018:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019		2018			2019		2018
Net revenues:
OSUR	$	17,730	$	19,258		$	56,335	$	65,623
DNAG		18,259		26,627			48,602		65,874
Total	$	35,989	$	45,885		$	104,937	$	131,497
Operating income (loss):
OSUR	$	8,080	$	(2,344	)	$	4,595	$	(13,654	)
DNAG		4,972		13,201			9,931		29,571
Total	$	13,052	$	10,857		$	14,526	$	15,917
Depreciation and amortization:
OSUR	$	889	$	879		$	2,555	$	2,883
DNAG		1,033		963			2,977		2,705
Total	$	1,922	$	1,842		$	5,532	$	5,588
Capital expenditures:
OSUR	$	1,796	$	908		$	5,341	$	3,682
DNAG		652		546			2,620		2,256
Total	$	2,448	$	1,454		$	7,961	$	5,938

	September 30, 2019		December 31, 2018
Total assets:
OSUR	$	181,133	$	190,178
DNAG		158,088		125,393
Total	$	339,221	$	315,571

Subsequent Events

9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

14.	SUBSEQUENT EVENTS:

On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen, Inc. (“Diversigen”), pursuant to the terms of a merger agreement. Diversigen is a Texas-based microbiome laboratory services provider that provides metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome.

The initial aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above. The merger agreement also includes a contingent payment to be paid based on Diversigen’s performance during the 2019 calendar year.

Through September 30, 2019, we incurred a total of $448 of acquisition related costs, including investment banking fees and accounting, legal and other professional fees, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income for the nine months ended September 30, 2019.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Investments

The following is a summary of our available-for-sale securities as of September 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2019
Guaranteed investment certificates	$	24,181	$	—	$	—		$	24,181
Corporate bonds		91,637		286		(326	)		91,597
Total available-for-sale securities	$	115,818	$	286	$	(326	)	$	115,778
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At September 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	78,271	$	183	$	(239	)	$	78,215
Greater than one year	$	37,547	$	103	$	(87	)	$	37,563

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of September 30, 2019 and December 31, 2018.

See Note 3 for discussion of the contingent consideration liabilities.

Accounts Receivable

Inventories

Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	September 30, 2019		December 31, 2018
Raw materials	$	14,425	$	14,092
Work in process		838		544
Finished goods		9,777		8,252
	$	25,040	$	22,888

Property, Plant and Equipment

The computations of basic and diluted earnings per share are as follows:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2019		2018		2019		2018

Net income	$	13,078	$	8,096	$	14,218	$	10,098
Weighted-average shares of common stock outstanding:
Basic		61,726		61,208		61,656		61,059
Dilutive effect of stock options, restricted stock, and performance stock units		417		1,398		516		1,480
Diluted		62,143		62,606		62,172		62,539
Earnings per share:
Basic	$	0.21	$	0.13	$	0.23	$	0.17
Diluted	$	0.21	$	0.13	$	0.23	$	0.16

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019		2018
OraQuick®	$	13,256		$	12,016	$	37,813	$	40,813
Oragene®		11,590			22,450		27,316		52,799
ORAcollect®		2,489			1,353		9,032		3,460
Intercept®		2,230			1,743		6,144		5,811
Histofreezer® (through August 16, 2019)		569			2,199		5,718		6,526
Other products		5,165			3,689		14,875		11,177
Net product revenues		35,299			43,450		100,898		120,586

Royalty income		758			1,132		2,956		4,827
Research and development funding		(183	)		1,083		679		4,540
Charitable support reimbursement		85			220		203		1,544
Grant funding		30			-		201		-
Other revenues		690			2,435		4,039		10,911
Net revenues	$	35,989		$	45,885	$	104,937	$	131,497

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	26,245	$	36,883	$	74,712	$	99,860
Europe		2,767		1,982		8,188		7,187
Other regions		6,977		7,020		22,037		24,450
	$	35,989	$	45,885	$	104,937	$	131,497

Customer and Vendor Concentrations

Deferred Revenue

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of September 30, 2019 and December 31, 2018:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
September 30, 2019
Guaranteed investment certificates	$	24,181	$	—	$	—		$	24,181
Corporate bonds		91,637		286		(326	)		91,597
Total available-for-sale securities	$	115,818	$	286	$	(326	)	$	115,778
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
At September 30, 2019, maturities of our available-for-sale securities were as follows:
Less than one year	$	78,271	$	183	$	(239	)	$	78,215
Greater than one year	$	37,547	$	103	$	(87	)	$	37,563

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:

	September 30, 2019		December 31, 2018
Raw materials	$	14,425	$	14,092
Work in process		838		544
Finished goods		9,777		8,252
	$	25,040	$	22,888

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2019		2018		2019		2018

Net income	$	13,078	$	8,096	$	14,218	$	10,098
Weighted-average shares of common stock outstanding:
Basic		61,726		61,208		61,656		61,059
Dilutive effect of stock options, restricted stock, and performance stock units		417		1,398		516		1,480
Diluted		62,143		62,606		62,172		62,539
Earnings per share:
Basic	$	0.21	$	0.13	$	0.23	$	0.17
Diluted	$	0.21	$	0.13	$	0.23	$	0.16

Business Combinations (Tables)

9 Months Ended

Sep. 30, 2019

Business Combinations [Abstract]

Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:

Assets Acquired
Accounts receivable	$	791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350	)
Net Cash Paid (net of cash acquired of $103)	$	13,217

Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives

The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:

	Estimated Useful
Description	Life (in yrs)	Amount
Developed Technology	10	$	5,000
Customer relationships	10		2,200
Tradenames	8.34		1,200
Total acquired intangibles		$	8,400

Summary of Unaudited Pro Forma Financial Information

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018

Revenue	$	35,989	$	46,628	$	104,937	$	133,150
Net income		13,078		7,649		14,218		7,335
Net income per share, basic and diluted		0.21		0.12		0.23		0.11

Revenues (Tables)

9 Months Ended

Sep. 30, 2019

Revenue From Contract With Customer [Abstract]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019		2018
OraQuick®	$	13,256		$	12,016	$	37,813	$	40,813
Oragene®		11,590			22,450		27,316		52,799
ORAcollect®		2,489			1,353		9,032		3,460
Intercept®		2,230			1,743		6,144		5,811
Histofreezer® (through August 16, 2019)		569			2,199		5,718		6,526
Other products		5,165			3,689		14,875		11,177
Net product revenues		35,299			43,450		100,898		120,586

Royalty income		758			1,132		2,956		4,827
Research and development funding		(183	)		1,083		679		4,540
Charitable support reimbursement		85			220		203		1,544
Grant funding		30			-		201		-
Other revenues		690			2,435		4,039		10,911
Net revenues	$	35,989		$	45,885	$	104,937	$	131,497

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	26,245	$	36,883	$	74,712	$	99,860
Europe		2,767		1,982		8,188		7,187
Other regions		6,977		7,020		22,037		24,450
	$	35,989	$	45,885	$	104,937	$	131,497

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

	September 30, 2019		December 31, 2018
Payroll and related benefits	$	6,250	$	8,926
Professional fees		1,101		1,541
Income taxes payable		74		1,447
Other		3,549		1,947
	$	10,974	$	13,861

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
Operating Lease Cost	$	232	$	695
Finance Lease Cost
Amortization of right-of use assets		112		264
Interest on lease liabilities		10		23
Total Finance Lease Cost	$	122	$	287

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Three months ended		Nine months ended
	September 30, 2019		September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	232	$	690
Operating cash flows from financing leases		10		23
Financing cash flows from financing leases		129		253
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		-		240
Right-of-use assets obtained in exchange for finance lease obligations		-		1,249

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	September 30, 2019
Operating Leases
Right-of-use assets	$	3,574

Current lease liabilities		761
Non-current lease liabilities		3,053
Total operating lease liabilities	$	3,814


Finance Leases
Right-of-use assets	$	1,276

Current lease liabilities		439
Non-current lease liabilities		829
Total finance lease liabilities	$	1,268

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4.89
Weighted-average remaining lease term—finance leases	3.25

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.23	%
Weighted-average discount rate—finance leases	2.82	%

Schedule of Minimum Lease Payments by Period Expected

As of September 30, 2019, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2019 (excluding the nine months ended September 30, 2019)	$	120		$	231
2020		454			951
2021		325			923
2022		324			898
2023		94			542
Thereafter		4			807
Total Minimum Lease Payments		1,321			4,352
Less: imputed interest		(53	)		(538	)
Present Value of Lease Liabilities	$	1,268		$	3,814

Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases

As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Summary of Reconciliation of Changes in Stockholders' Equity

Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2019 and 2018
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2018		61,276		$	—	$	401,273		$	(18,706	)	$	(99,189	)	$	283,378
Common stock issued upon exercise of options		4			—		22			—			—			22
Vesting of restricted stock and performance stock units		664			—		—			—			—			—
Purchase and retirement of common shares		(277	)		—		(3,595	)		—			—			(3,595	)
Compensation cost for restricted stock		—			—		653			—			—			653
Compensation cost for stock option grants		—			—		324			—			—			324
Compensation cost for performance stock units		—			—		254			—			—			254
Net loss		—			—		—			—			(3,258	)		(3,258	)
Currency translation adjustments										2,232						2,232
Unrealized gain on marketable securities		—			—		—			497			—			497
Balance at March 31, 2019		61,667		$	—	$	398,931		$	(15,977	)	$	(102,447	)	$	280,507
Common stock issued upon exercise of options		18			—		147			—			—			147
Vesting of restricted stock and performance stock units		51			—		—			—			—			—
Purchase and retirement of common shares		(11	)		—		(109	)		—			—			(109	)
Compensation cost for restricted stock		—			—		874			—			—			874
Compensation cost for stock option grants		—			—		311			—			—			311
Compensation cost for performance stock units		—			—		(569	)		—			—			(569	)
Net income		—			—		—			—			4,398			4,398
Currency translation adjustments										2,476						2,476
Unrealized gain on marketable securities		—			—		—			186			—			186
Balance at June 30, 2019		61,725		$	—	$	399,585		$	(13,315	)	$	(98,049	)	$	288,221
Common stock issued upon exercise of options		-			—		—			—			—			-
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(7	)		—			—			(7	)
Compensation cost for restricted stock		-			—		858			—			—			858
Compensation cost for stock option grants		-			—		259			—			—			259
Compensation cost for performance stock units		-			—		319			—			—			319
Net income		-			—		—			—			13,078			13,078
Currency translation adjustments										(1,557	)					(1,557	)
Unrealized gain on marketable securities		-			—		—			194			—			194
Balance at September 30, 2019		61,726		$	—	$	401,014		$	(14,678	)	$	(84,971	)	$	301,365


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2017		60,662		$	—	$	387,931		$	(10,340	)	$	(119,510	)	$	258,081
Adoption of ASU 2014-9													(75	)		(75	)
Common stock issued upon exercise of options		133			—		974			—			—			974
Vesting of restricted stock and performance stock units		407			—		—			—			—			—
Purchase and retirement of common shares		(149	)		—		(2,959	)		—			—			(2,959	)
Compensation cost for restricted stock		—			—		3,626			—			—			3,626
Compensation cost for stock option grants		—			—		900			—			—			900
Compensation cost for performance stock units		—			—		2,957			—			—			2,957
Net loss		—			—		—			—			(2,119	)		(2,119	)
Currency translation adjustments										(2,154	)					(2,154	)
Unrealized loss on marketable securities		—			—		—			(512	)		—			(512	)
Balance at March 31, 2018		61,053		$	—	$	393,429		$	(13,006	)	$	(121,704	)	$	258,719
Common stock issued upon exercise of options		29			—		222			—			—			222
Vesting of restricted stock and performance stock units		106			—		—			—			—			—
Purchase and retirement of common shares		(14	)		—		(212	)		—			—			(212	)
Compensation cost for restricted stock		—			—		1,419			—			—			1,419
Compensation cost for stock option grants		—			—		475			—			—			475
Compensation cost for performance stock units		—			—		1,885			—			—			1,885
Net income		—			—		—			—			4,121			4,121
Currency translation adjustments										(1,652	)					(1,652	)
Unrealized gain on marketable securities		—			—		—			194			—			194
Balance at June 30, 2018		61,174		$	—	$	397,218		$	(14,464	)	$	(117,583	)	$	265,171
Common stock issued upon exercise of options		62			—		483			—			—			483
Vesting of restricted stock and performance stock units		2			—		—			—			—			—
Purchase and retirement of common shares		(1	)		—		(9	)		—			—			(9	)
Compensation cost for restricted stock		—			—		589			—			—			589
Compensation cost for stock option grants		—			—		359			—			—			359
Compensation cost for performance stock units		—			—		316			—			—			316
Net income		—			—		—			—			8,096			8,096
Currency translation adjustments										1,783						1,783
Unrealized loss on marketable securities		—			—		—			(34	)		—			(34	)
Balance at September 30, 2018		61,237		$	—	$	398,956		$	(12,715	)	$	(109,487	)	$	276,754

Business Segment Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and nine months ended September 30, 2019 and 2018, and asset information as of September 30, 2019 and December 31, 2018:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019		2018			2019		2018
Net revenues:
OSUR	$	17,730	$	19,258		$	56,335	$	65,623
DNAG		18,259		26,627			48,602		65,874
Total	$	35,989	$	45,885		$	104,937	$	131,497
Operating income (loss):
OSUR	$	8,080	$	(2,344	)	$	4,595	$	(13,654	)
DNAG		4,972		13,201			9,931		29,571
Total	$	13,052	$	10,857		$	14,526	$	15,917
Depreciation and amortization:
OSUR	$	889	$	879		$	2,555	$	2,883
DNAG		1,033		963			2,977		2,705
Total	$	1,922	$	1,842		$	5,532	$	5,588
Capital expenditures:
OSUR	$	1,796	$	908		$	5,341	$	3,682
DNAG		652		546			2,620		2,256
Total	$	2,448	$	1,454		$	7,961	$	5,938

	September 30, 2019		December 31, 2018
Total assets:
OSUR	$	181,133	$	190,178
DNAG		158,088		125,393
Total	$	339,221	$	315,571

The Company - Additional Information (Detail)	9 Months Ended
The Company - Additional Information (Detail)	Sep. 30, 2019 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 115,818	$ 113,803
Gross Unrealized Gains	286	0
Gross Unrealized Losses	(326)	(917)
Fair Value	115,778	112,886
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,181	23,096
Gross Unrealized Gains	0	0
Fair Value	24,181	23,096
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	91,637	90,707
Gross Unrealized Gains	286	0
Gross Unrealized Losses	(326)	(917)
Fair Value	91,597	$ 89,790
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	78,271
Gross Unrealized Gains	183
Gross Unrealized Losses	(239)
Fair Value	78,215
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	37,547
Gross Unrealized Gains	103
Gross Unrealized Losses	(87)
Fair Value	$ 37,563

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 04, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents		$ 85,465		$ 85,465			$ 88,438
Fair value of plan assets		4,280		4,280			3,884
Accumulated depreciation of property and equipment		45,533		45,533			42,797
Accumulated amortization of intangible assets		22,410		22,410			20,105
Intangible Assets, Net		11,577		11,577			5,137
Amount of goodwill at period end		28,935		28,935			18,521
Increase in goodwill associated with foreign currency translation				420
Right-of-use assets						$ 4,027
Lease liabilities						$ 4,263
Net foreign exchange gains (losses)		50	$ (375)	(875)	$ (30)
Accumulated foreign currency adjustments included in other comprehensive loss amounted		14,638		14,638			17,789
Unrealized loss on marketable securities		$ 40		$ 40			917
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation		909	304	709	256
Corebiome Inc. and Novosanis NV [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Accumulated Amortization				$ 1,831
Intangible Assets, acquired	$ 8,400
Intangible Assets, Foreign currency translation loss				129
Amount of goodwill at period end	$ 9,994
Goodwill, acquired during period				$ 9,994
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets				5 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets				15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets				10 years
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents		$ 18,790		$ 18,790			$ 21,631

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Net [Abstract]
Raw materials	$ 14,425	$ 14,092
Work in process	838	544
Finished goods	9,777	8,252
Inventories	$ 25,040	$ 22,888

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net income	$ 13,078	$ 4,398	$ (3,258)	$ 8,096	$ 4,121	$ (2,119)	$ 14,218	$ 10,098
Weighted-average shares of common stock outstanding:
Basic	61,726			61,208			61,656	61,059
Dilutive effect of stock options, restricted stock, and performance stock units	417			1,398			516	1,480
Diluted	62,143			62,606			62,172	62,539
Basic	$ 0.21			$ 0.13			$ 0.23	$ 0.17
Diluted	$ 0.21			$ 0.13			$ 0.23	$ 0.16

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended						9 Months Ended
	Oct. 31, 2019	Jan. 04, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Acquisition-related costs									$ 448
Business acquisition contingent consideration, non-current			$ 385						385
Change in the estimated fair value of acquisition-related contingent consideration			(2,387)						(843)
Revenues			35,989			$ 45,885			104,937	$ 131,497
Net income (loss)			13,078	$ 4,398	$ (3,258)	$ 8,096	$ 4,121	$ (2,119)	14,218	$ 10,098
Subsequent Event [Member]
Business Acquisition [Line Items]
Business acquisition contingent consideration	$ 3,500
Change in the estimated fair value of acquisition-related contingent consideration	$ 500
Corebiome Inc. and Novosanis NV [Member]
Business Acquisition [Line Items]
Purchase price		$ 13,320
Acquisition-related costs									597
Business acquisition contingent consideration, non-current			32,400						$ 32,400
Business combination contingent consideration expected payment period									3 years
Estimated fair value of contingent consideration		$ 4,350
Business acquisition contingent consideration			3,424						$ 3,424
Revenues			1,437						3,482
Net income (loss)			$ 1,377						$ (1,142)

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 04, 2019	Dec. 31, 2018
Assets Acquired
Goodwill	$ 28,935		$ 18,521
Corebiome Inc. and Novosanis NV [Member]
Assets Acquired
Accounts receivable		$ 791
Inventories		310
Other current assets		82
Property, plant, and equipment, net		414
Other assets		5
Acquired intangible assets		8,400
Goodwill		9,994
Total assets acquired		19,996
Liabilities Assumed
Current liabilities		1,180
Notes payable, short-term		730
Deferred tax liability		445
Other long-term liabilities		74
Total liabilities assumed		2,429
Net Assets Acquired		17,567
Estimated fair value of contingent consideration		(4,350)
Net Cash Paid (net of cash acquired of $103)		$ 13,217

Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - USD ($) $ in Thousands		9 Months Ended
	Jan. 04, 2019	Sep. 30, 2019
Business Acquisition [Line Items]
Net of cash acquired	$ 103	$ 13,217

Business Combinations - Summary of Identifiable Intangible Assets Subject to Amortization on Straight-line Basis and Being Amortized over Estimated Useful Lives (Detail) - Corebiome Inc. and Novosanis NV [Member] $ in Thousands	Jan. 04, 2019 USD ($)
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 8,400
Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 5,000
Acquired intangibles, Estimated Useful Life	10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 2,200
Acquired intangibles, Estimated Useful Life	10 years
Tradenames [Member]
Business Acquisition [Line Items]
Acquired intangibles, Amount	$ 1,200
Acquired intangibles, Estimated Useful Life	8 years 4 months 2 days

Business Combinations - Summary of Unaudited Pro Forma Financial Information (Detail) - Corebiome Inc. and Novosanis NV [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Revenue	$ 35,989	$ 46,628	$ 104,937	$ 133,150
Net income	$ 13,078	$ 7,649	$ 14,218	$ 7,335
Net income per share, basic and diluted	$ 0.21	$ 0.12	$ 0.23	$ 0.11

Sale of Cryosurgical Systems Business - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Aug. 16, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on sale of business	$ 10,149	$ 10,149
Proceeds from sale of business		12,000
Cryosurgical Systems
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Consideration receivable from sale of business			$ 12,000
Gain on sale of business	$ 10,149	10,149
Proceeds from sale of business		$ 12,000

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 35,989	$ 45,885	$ 104,937	$ 131,497
Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	35,299	43,450	100,898	120,586
Product Revenues [Member] \| OraQuick [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	13,256	12,016	37,813	40,813
Product Revenues [Member] \| Oragene [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,590	22,450	27,316	52,799
Product Revenues [Member] \| ORAcollect [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,489	1,353	9,032	3,460
Product Revenues [Member] \| Intercept [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,230	1,743	6,144	5,811
Product Revenues [Member] \| Histofreezer (through August 16, 2019) [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	569	2,199	5,718	6,526
Product Revenues [Member] \| Other Products [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	5,165	3,689	14,875	11,177
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	690	2,435	4,039	10,911
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	758	1,132	2,956	4,827
Other [Member] \| Research and Development Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	(183)	1,083	679	4,540
Other [Member] \| Charitable Support Reimbursement [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	85	$ 220	203	$ 1,544
Other [Member] \| Grant Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 30		$ 201

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Net revenues	$ 35,989	$ 45,885	$ 104,937	$ 131,497
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	26,245	36,883	74,712	99,860
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,767	1,982	8,188	7,187
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 6,977	$ 7,020	$ 22,037	$ 24,450

Revenues - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
Revenues - Additional Information (Detail) $ in Thousands	Sep. 30, 2019 USD ($) Supplier	Sep. 30, 2018	Sep. 30, 2019 USD ($) Supplier	Sep. 30, 2018	Dec. 31, 2018 USD ($)
Revenue from contract with customer [Line Items]
Deferred revenue	$ 3,940		$ 3,940		$ 3,521
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,790		1,790		1,464
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 2,150		$ 2,150		$ 2,057
DNA Genotek [Member]
Revenue from contract with customer [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier	2		2
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk			24.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	17.00%	39.00%	11.00%	27.00%

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 6,250	$ 8,926
Professional fees	1,101	1,541
Income taxes payable	74	1,447
Other	3,549	1,947
Accrued expenses and other current liabilities, Total	$ 10,974	$ 13,861

Leases - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate		true
Lessee operating and financing leases, period of options to terminate		1 year
Lessee, operating and finance lease, existence of option to extend		true
Lease cost	$ 368		$ 1,097
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms		8 years

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Lease Cost [Abstract]
Operating Lease Cost	$ 232	$ 695
Finance Lease Cost
Amortization of right-of use assets	112	264
Interest on lease liabilities	10	23
Total Finance Lease Cost	$ 122	$ 287

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 232	$ 690
Operating cash flows from financing leases	10	23
Financing cash flows from financing leases	$ 129	253
Non-cash activity
Right-of-use assets obtained in exchange for operating lease obligations		240
Right-of-use assets obtained in exchange for finance lease obligations		$ 1,249

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Operating Leases
Right-of-use assets	$ 3,574
Current lease liabilities	761
Non-current lease liabilities	3,053
Total operating lease liabilities	3,814
Finance Leases
Right-of-use assets	1,276
Current lease liabilities	439
Non-current lease liabilities	829
Total finance lease liabilities	$ 1,268

Leases - Summary of Lease Term and Discount Rate (Detail)	Sep. 30, 2019
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	4 years 10 months 20 days
Weighted-average remaining lease term—finance leases	3 years 3 months
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.23%
Weighted-average discount rate—finance leases	2.82%

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Finance Lease Liabilities, Payments, Due [Abstract]
2019 (excluding the nine months ended September 30, 2019)	$ 120
2020	454
2021	325
2022	324
2023	94
Thereafter	4
Total Minimum Finance Lease Payments	1,321
Less: imputed interest	(53)
Present Value of Finance Lease Liabilities	1,268
Operating Lease Liabilities, Payments Due [Abstract]
2019 (excluding the nine months ended September 30, 2019)	231
2020	951
2021	923
2022	898
2023	542
Thereafter	807
Total Minimum Operating Lease Payments	4,352
Less: imputed interest	(538)
Present Value of Operating Lease Liabilities	$ 3,814

Leases - Schedule of Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 903
2020	902
2021	877
2022	850
2023	506
Thereafter	737
Total	$ 4,775

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Beginning Balance	$ 288,221	$ 280,507	$ 283,378	$ 265,171	$ 258,719	$ 258,081	$ 283,378	$ 258,081
Adoption of ASU 2014-9						(75)
Common stock issued upon exercise of options		147	22	483	222	974
Purchase and retirement of common shares	(7)	(109)	(3,595)	(9)	(212)	(2,959)
Compensation cost for restricted stock	858	874	653	589	1,419	3,626
Compensation cost for stock option grants	259	311	324	359	475	900
Compensation cost for performance stock units	319	(569)	254	316	1,885	2,957
Net income (loss)	13,078	4,398	(3,258)	8,096	4,121	(2,119)	14,218	10,098
Currency translation adjustments	(1,557)	2,476	2,232	1,783	(1,652)	(2,154)	3,151	(2,023)
Unrealized gain (loss) on marketable securities	194	186	497	(34)	194	(512)	877	(352)
Ending Balance	$ 301,365	$ 288,221	$ 280,507	$ 276,754	$ 265,171	$ 258,719	$ 301,365	$ 276,754
Common Stock [Member]
Beginning Balance, Shares	61,725	61,667	61,276	61,174	61,053	60,662	61,276	60,662
Common stock issued upon exercise of options, Shares		18	4	62	29	133
Vesting of restricted stock and performance stock units, Shares	2	51	664	2	106	407
Purchase and retirement of common shares, Shares	(1)	(11)	(277)	(1)	(14)	(149)
Ending Balance, Shares	61,726	61,725	61,667	61,237	61,174	61,053	61,726	61,237
Additional Paid-in Capital [Member]
Beginning Balance	$ 399,585	$ 398,931	$ 401,273	$ 397,218	$ 393,429	$ 387,931	$ 401,273	$ 387,931
Common stock issued upon exercise of options		147	22	483	222	974
Purchase and retirement of common shares	(7)	(109)	(3,595)	(9)	(212)	(2,959)
Compensation cost for restricted stock	858	874	653	589	1,419	3,626
Compensation cost for stock option grants	259	311	324	359	475	900
Compensation cost for performance stock units	319	(569)	254	316	1,885	2,957
Ending Balance	401,014	399,585	398,931	398,956	397,218	393,429	401,014	398,956
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(13,315)	(15,977)	(18,706)	(14,464)	(13,006)	(10,340)	(18,706)	(10,340)
Currency translation adjustments	(1,557)	2,476	2,232	1,783	(1,652)	(2,154)
Unrealized gain (loss) on marketable securities	194	186	497	(34)	194	(512)
Ending Balance	(14,678)	(13,315)	(15,977)	(12,715)	(14,464)	(13,006)	(14,678)	(12,715)
Accumulated Deficit [Member]
Beginning Balance	(98,049)	(102,447)	(99,189)	(117,583)	(121,704)	(119,510)	(99,189)	(119,510)
Adoption of ASU 2014-9						(75)
Net income (loss)	13,078	4,398	(3,258)	8,096	4,121	(2,119)
Ending Balance	$ (84,971)	$ (98,049)	$ (102,447)	$ (109,487)	$ (117,583)	$ (121,704)	$ (84,971)	$ (109,487)

Stockholders' Equity - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 3,283,000	$ 12,526,000
Amount share repurchase program of common shares			$ 25,000,000
Retiring President and Chief Executive Officer and Chief Financial Officer [Member] \| General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost		8,039,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	894,000	1,734,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 2,385,000	$ 5,634,000
Vesting of restricted shares, withholding and exercise obligations	289,000	164,000
Restricted shares of common stock, aggregate values	$ 3,711,000	$ 3,181,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 4,000	$ 5,158,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,169,000	$ 3,271,000	$ 2,551,000	$ 7,477,000
U.S. federal or state deferred income tax expense or benefits	$ 0		$ 0

Transition Costs - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
General and Administrative Expenses [Member]
Transition Costs [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 0	$ 8,628,000

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2019 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net revenues	$ 35,989	$ 45,885	$ 104,937	$ 131,497
Operating income (loss)	13,052	10,857	14,526	15,917
Depreciation and amortization	1,922	1,842	5,532	5,588
Capital expenditures	2,448	1,454	7,961	5,938
Total assets	339,221		339,221		$ 315,571
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	17,730	19,258	56,335	65,623
Operating income (loss)	8,080	(2,344)	4,595	(13,654)
Depreciation and amortization	889	879	2,555	2,883
Capital expenditures	1,796	908	5,341	3,682
Total assets	181,133		181,133		190,178
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	18,259	26,627	48,602	65,874
Operating income (loss)	4,972	13,201	9,931	29,571
Depreciation and amortization	1,033	963	2,977	2,705
Capital expenditures	652	$ 546	2,620	$ 2,256
Total assets	$ 158,088		$ 158,088		$ 125,393

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Nov. 08, 2019	Sep. 30, 2019
Subsequent Event [Line Items]
Acquisition-related costs		$ 448
Diversigen, Inc. [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase price	$ 12,000